Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR-T therapy targets tough childhood blood cancers

NCT ID NCT07623681

Not yet recruiting Disease control Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new treatment called PA3-17 injection for children and teens aged 3 to 18 with T-cell leukemia or lymphoma that has not responded to standard therapy or has come back. The treatment uses the patient's own immune cells, modified to recognize and attack cancer cells carrying a protein called CD7. The main goals are to find a safe dose and check for side effects, with a small group of 12 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PA3-17 injection (a type of CAR-T cell therapy targeting CD7)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat T-cell leukemia or lymphoma that has come back after other treatments.
What could go wrong
This is a very early, small Phase 1 trial with only 12 participants, so it is mainly checking safety and dosing. The treatment may not work, and there are risks like severe immune reactions or side effects from the cell therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD7+ T-ALL/LBL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

early T cell progenitor acute lymphoblastic leukemia refractory precursor T-lymphoblastic lymphoma/leukemia T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CD7+ T-ALL/LBL

Contacts and locations

Locations

  • PersonGen Anke Cellular Therapeutice Co,Ltd.

    Hefei, Anhui, 230088, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.